process. It offers diagnostic and research assays in the areas of virology, blood screening, women's health, HPV and chlamydia trachomatis/neisseria gonorrhoeae, and microbiology and genomics, as well as develops tests in the area of oncology. The company also provides PCR-based nucleic acid tests and automation that enables the detection of active HIV, Hepatitis C, and Hepatitis B infections, as well as enables to reduce transmission of these diseases during transfusions, transplantations, or administration of other medical therapies derived from blood products. In addition, it offers clinical laboratory system, which combines CE-marked in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. The company was incorporated in 1991 and is headquartered in Pleasanton, California. It has research, development, manufacturing, and distribution facilities in the United States, Germany, and Switzerland. Roche Molecular Systems, Inc. operates as a subsidiary of Roche Diagnostics Corporation.